Renub Research has recently published a report named “Non-Invasive Prenatal Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2022-2030,” providing a detailed industry analysis that consists of market share insights. Furthermore, the report encompasses a study of competitors and regions and the recent growth in the Non-Invasive Prenatal Testing (NIPT) Market.
Expert Insights: Ask Analyst or Download Full Report with TOC & Figures: https://www.renub.com/non-invasive-prenatal-testing-market-p.php
A CAGR of 13.60% is expected for the Non-Invasive Prenatal Testing Market between 2022 and 2030.The development of technology over the years has made it possible to identify more minor genetic anomalies, including numerous single-gene disorders. The non-invasive prenatal test (NIPT) is the most recent advancement in the field of prenatal diagnosis. It is intended to assist professionals in the management of pregnancy and its counselling as well as prospective parents in making deliberate and well-informed decisions regarding their unborn child.
Prenatal diagnosis is evolving all over the world thanks to non-invasive prenatal testing (NIPT). It offers high specificity and sensitivity for detecting common aneuploidies. As a result, it has decreased the frequency of invasive procedures and the risk of miscarriage that goes along with them. Cell-free fetal DNA (cffDNA), which is obtained from a maternal peripheral blood sample, serves as the foundation for NIPT.
The performance of NIPT has recently improved, and new applications have been made possible thanks to advanced laboratory detection and purification technology. The development of Next Generation Sequencing (NGS) into clinical practice has increased the sensitivity of NIPT for aneuploidy screening. It has also made it possible to identify and research the fetal genome from maternal plasma. Fetal Whole Exome Sequencing (WES) enables non-invasive prenatal diagnosis of inherited monogenic disorders and can identify the underlying cause of fetal anomalies with a normal karyotype.
The landscape of prenatal screening has changed significantly since non-invasive prenatal testing (NIPT) for the detection of fetal aneuploidies was introduced into clinical practice in 2011. More than 10 million people take the test annually, which is accessible in more than 60 countries. The rapid adoption of NIPT was facilitated by demand from expectant mothers and medical professionals, technological advancements, and financial incentives.
Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=non-invasive-prenatal-testing-market-p.php
Page Contents
Cell-free DNA tests, which are becoming more and more popular, are anticipated to rule the Non-Invasive Prenatal Testing Market in the upcoming years
CfDNA tests in maternal plasma are the most widely used option on the global NIPT market because of their high accuracy, dependability, and sensitivity of over 99% for detecting trisomy 21. They are accessible as early as 10 weeks of pregnancy and do not require invasive procedures like amniocentesis, which appeals to many pregnant women. They can also be used by a wider variety of expectant mothers due to their affordability. These benefits have made cfDNA tests more and more well-liked, and they are anticipated to take over the global NIPT market in the future.
Method – Non-Invasive Prenatal Testing (NIPT) Market has been covered from 4 viewpoints:
1. Ultrasound detection
2. Biochemical screening tests
3. Cell-free DNA in maternal plasma tests
4. Others
Enzyme-Linked Immunosorbent Assay (ELISA) Kits, are the global Non-Invasive Prenatal Testing (NIPT) market’s fastest-growing subsegment worldwide.
The versatility of ELISA kits in identifying a variety of analytes, such as antibodies, antigens, hormones, and enzymes, makes them appropriate for a variety of clinical and research applications. Their high sensitivity and specificity guarantee accurate results and reliable detection of even minute amounts of analyte. ELISA kits are also user-friendly, making them accessible to labs with limited resources, and their cost-effectiveness makes them a good option for labs on a tight budget. Moreover, the market is expanding as a result of the rising demand for point-of-care (POC) testing. Due to their simplicity of use and suitability for testing with minimal equipment, ELISA kits are a good choice for POC testing.
Technology – Non-Invasive Prenatal Testing Market has been covered from 3 viewpoints:
1. ELISA Kits (Enzyme-Linked Immunosorbent Assay Kits)
2. Next Generation Sequencing Systems
3. Microarray Analysis
The high- and average-risk segments are expected to continue to dominate the Non-Invasive Prenatal Testing (NIPT) Market in the years to come.
High-risk pregnancies have a higher prevalence of chromosomal abnormalities, which increases the risk of such abnormalities due to factors like maternal age and family history. The high chromosomal abnormality detection accuracy of NIPT in high-risk pregnancies is advantageous to both pregnant women and medical professionals. More pregnant women, including those at high or average risk, can now access NIPT at an affordable price thanks to its increased accessibility and falling price.
Risk Type – Non-Invasive Prenatal Testing Market has been covered from 2 viewpoints:
1. High & Average risk
2. Low risk
The majority of global Non-Invasive Prenatal testing businesses are diagnostic facilities.
Diagnostic centers have an advantage in the global NIPT market due to their expertise, experience, and access to cutting-edge technology. They effectively carry out NIPT with qualified specialists acquainted with its subtleties. Furthermore, they provide practical one-stop services that make it simple for expectant women to get tested and receive results in a timely manner, fostering patient trust thanks to their track record of delivering accurate and dependable results and accreditation by regulatory bodies.
End-User – Non-Invasive Prenatal Testing (NIPT) Market has been covered from 3 viewpoints:
1. Specialty Centers
2. Hospitals
3. Diagnostic Centers
The United States is expected to keep holding a commanding share in the Non-Invasive Prenatal Testing (NIPT) Market over the coming years.
The prevalence of chromosomal abnormalities is higher in the nation as a result of elements like maternal age, family history, and race. Due to media coverage, marketing initiatives, and insurance reimbursement policies, NIPT is also well-known among pregnant women and medical professionals. A favorable regulatory environment and the availability of numerous NIPT companies both support the market’s expansion. For the development and interpretation of NIPT, the US also has the necessary technological and clinical capabilities.
Countries – Non-Invasive Prenatal Testing (NIPT) Market has been covered from 27 viewpoints:
1. North America
1.1 United States
1.2 Canada
2. Europe
2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherlands
2.8 Switzerland
2.9 Turkey
3. Asia Pacific
3.1 China
3.2 Japan
3.3 India
3.4 Australia
3.5 South Korea
3.6 Thailand
3.7 Malaysia
3.8 Indonesia
3.9 Philippines
4. Latin America
4.1 Brazil
4.2 Mexico
4.3 Argentina
5. Middle East & Africa
5.1 South Africa
5.2 Saudi Arabia
5.3 UAE
6. Rest of the World
Competitive Landscape.
F. Hoffman-La Roche, Eurofins Scientific, Illumina, Natera Inc., Revvity Inc., Thermo Fisher Scientific, Quest Diagnostics, and Agilent Technologies are some of the top competitors in the global non-invasive prenatal testing market.
All companies have been covered from 3 viewpoints:
• Overview
• Recent Development
• Revenue
Company Analysis:
1. F. Hoffman-La Roche
2. Eurofins Scientific
3. Illumina
4. Natera Inc.
5. Revvity Inc.
6. Thermo Fisher Scientific
7. Quest Diagnostics
8. Agilent Technologies
About the Company:
Renub Research is a Market Research and Information Analysis company with more than 14 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 7000 syndicated reports and worked on more than 500 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.
Media Contact:
Company Name: Renub Research
Contact Person: Rajat Gupta, Marketing Manager
Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)
Address: 225 Kristie Ln, Roswell, GA 30076
Email: info@renub.com
LinkedIn: https://linkedin.com/company/renub-research
